Woman’s Inoperable Brain Tumor Shrinks In Just Five Days Thanks To Cancer Breakthrough
Researchers at Mass General Brigham are reporting striking early results from an experimental treatment targeting Glioblastoma, one of the most aggressive and difficult-to-treat brain cancers.
In March 2024, doctors tested a modified form of CAR‑T therapy on three patients whose tumors had returned after standard treatment. The team combined the cell-based immunotherapy with targeted antibodies designed to help engineered immune cells recognize and attack the cancer more precisely.
Instead of delivering the treatment through the bloodstream, researchers injected it directly into the cerebrospinal fluid surrounding the brain and spinal cord. The approach was intended to place the modified immune cells closer to the tumor and overcome barriers that often prevent treatments from reaching brain tissue.
The early responses surprised the research team. One patient’s tumor shrank by 18.5% within two days and by more than 60% after ten weeks. A second patient also experienced rapid tumor regression, while MRI scans of the third showed visible changes within five days of treatment.
Scientists caution that the results come from just three patients and represent an early-stage study rather than a proven cure. Still, the findings offer a rare sign of progress against glioblastoma, a cancer that has long resisted most therapies. For researchers and patients alike, the trial suggests the disease may finally have vulnerabilities that advanced immunotherapy could exploit.
